A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Her2 Amplified Solid Tumors|Metastatic Breast Cancer
Interventions: DRUG: MM-111
Sponsor: Merrimack Pharmaceuticals